Contraception
Volume 82, Issue 2 , Pages 119-124 , August 2010

Joseph W. Goldzieher and the birth of hormonal contraception

Received 26 February 2010 ,Accepted 9 March 2010.

References 

  1. Goldzieher JW, Rudel HW. How the oral contraceptives came to be developed. J Am Med Ass. 1974;230:421–425
  2. Diczfalusy E. Gregory Pincus and steroidal contraception: a new departure in the history of mankind. J Steroid Biochem. 1979;11:3–11
  3. Rice-Wray E. Twenty years of oral contraception. IPPF Med Bull. 1981;15:1–3
  4. Goldzieher MA. The endocrine glands. New York: Appleton-Century; 1939;
  5. Goldzieher MA. The adrenal gland in health and disease. Philadelphia: Davis; 1948;
  6. Goldzieher MA. Treatment of excessive growth in the adolescent female. J Clin Endocrinol Metab. 1956;16:249–252
  7. Goldzieher MA, Goldzieher JW. Toxic effects of percutaneously absorbed steroids. JAMA. 1949;140:1156
  8. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception. 2008;78:4–9
  9. Sartwell PE, Masi AT, Arthes FG, et al. Thromboembolism and oral contraceptives: an epidemiologic case/control study. Am J Epidemiol. 1969;90:365–380
  10. Goldzieher JW. Bust without boom. Contraception. 2000;61:27–28
  11. Goldzieher JW, Zamah NM. Oral contraceptive side effects: where's the beef?. Contraception. 1995;52:327–335
  12. Goldzieher JW. Estrogens in oral contraceptives: historical perspectives. Johns Hopkins Med J. 1982;150:165–169
  13. World Health Organization . Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. Geneva: WHO; 2004;
  14. Goldzieher MA, Reimer NA, Goldzieher JW. Metabolic abnormalities in obesity: a statistical survey. Am J Dig Dis. 1945;12:387–394
  15. Goldzieher JW, Popkin GL. Treatment of headache with intravenous sodium nicotinate. JAMA. 1946;131:103–105
  16. Goldzieher JW. A new colorimetric method for the determination of pregnanediol. J Lab Clin Med. 1948;33:251–253
  17. Goldzieher JW, Roberts IS. Identification of estrogen in the human testis. J Clin Endocrinol Metab. 1952;12:143–150
  18. Axelrod LR, Rao PN, Goldzieher JW. Methylation of 2-hydroxyestradiol-17β to 2-methoxyestrone in the human. Arch Biochem Biophys. 1960;87:152–153
  19. Axelrod LR, Goldzieher JW. The metabolism of 17α-hydroxyprogesterone and its relation to congenital adrenal hyperplasia. J Clin Endrocrinol Metab. 1960;20:283–297
  20. Savard K, Goldweber M, Goldzieher JW. Non utilization of mevalonic acid in steroidogenesis by testis tissue. Fed Proc. 1960;19:196
  21. Pincus G. Some effects of progesterone and related compounds upon reproduction and early development in mammals. Proc. 5th Internat Conf Planned Parenthood, Tokyo. Acta Endocrin (Khb). 1956;20(Suppl 28):175–184
  22. Zañartu J, Rice-Wray E, Goldzieher JW. Fertility control with long-acting injectable steroids: a preliminary report. Obstet Gynecol. 1966;28:513–515
  23. World Health Organization . Task force on long-acting injectable contraceptives. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enantathe given in two dosage regimens and depot-medroxyprogesterone acetate. A preliminary report. Contraception. 1982;25:1–11
  24. World Health Organization . Task force on long-acting injectable contraceptives. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enantathe given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception. 1983;28:1–20
  25. Goldzieher JW, Moses LE, Ellis LT. A field trial with a physiological method of conception control. In:  Kiser CV editors. Conference on Research in Family Planning, New York, 1960. Princeton (NJ): Princeton University Press; 1962;p. 351–356
  26. Goldzieher JW, Moses LE, Ellis LT. Study of norethindrone in contraception. JAMA. 1962;180:359–361
  27. Goldzieher JW. Clinical evaluation of contraceptives: a great responsibility. Yearbook Gynecol. 1965-1966;371–374
  28. Goldzieher JW, Rice-Wray E, Schulz-Contreras M, Aranda-Rossel A. Fertility following termination of contraception with norethindrone. Endometrial morphology and conception rate. Am J Obstet Gynecol. 1962;84:1474–1477
  29. Haus W, Goldzieher JW, Hamblen EC. Dysmenorrhea and ovulation. Correlation of the effect of estrogen therapy on pain, the endometrium and the basal body temperature. Am J Obstet Gynecol. 1947;54:820–828
  30. Martinez-Manatou J, Gual C, Goldzieher JW, Rudel HW. Comparative antiovulatory potency of certain natural and synthetic estrogens. In: Program Endocrine Soc, 46th Meeting San Francisco. Chevy Chase (MD): The Endocrine Society. 1964;p. 68;[no. 91]
  31. Gual C, Becerra C, Rice-Wray E, Goldzieher JW. Inhibition of ovulation by estrogens. Am J Obstet Gynecol. 1967;122:625–636
  32. Hines DC, Goldzieher JW. Large-scale study of an oral contraceptive. Fertil Steril. 1968;19:841–866
  33. Goldzieher JW, Maas JM, Hines DC. Seven years of clinical experience with a sequential oral contraceptive. Int J Fertil. 1968;13:399–404
  34. Kelley HW, Miles PA, Buster J, Scragg WH. Adenocarcinoma of the endometrium in women taking sequential oral contraceptives. Obstet Gynecol. 1976;47:200–202
  35. Goldzieher JW, Maqueo M, Chenault CB, Woutersz TB. Comparative studies of the ethynyl estrogens used in oral contraceptives. I. Endometrial response. Am J Obstet Gynecol. 1975;122:615–618
  36. Goldzieher JW, de la Peña A, Chenault CB, Woutersz TB. Comparative studies of the ethynyl estrogens used in oral contraceptives. II. Antiovulatory potency. Am J Obstet Gynecol. 1975;122:619–624
  37. Goldzieher JW, de la Peña A, Chenault CB, Cervantes A. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins. Am J Obstet Gynecol. 1975;122:625–636
  38. Goldzieher JW, Brody SA. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol. 1990;163:2114–2119
  39. Goldzieher JW. Pharmacology of contraceptive steroids: a brief review. Am J Obstet Gynecol. 1989;160:1260–1264
  40. Goldzieher JW. Pharmacokinetics and metabolism of ethinyl estrogens. In:  Goldzieher JW,  Fotherby K editor. Pharmacology of the contraceptive steroids. New York: Raven Press Ltd; 1994;p. 127–152
  41. Brody SA, Turkes A, Goldzieher JW. Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are “low-dose” pills really lower?. Contraception. 1989;40:269–284
  42. Maqueo M, Perez-Vega E, Goldzieher JW, Martinez-Manautou J, Rudel HW. Comparison of the endometrial activity of 3 synthetic progestins used in fertility control. Am J Obstet Gynecol. 1963;85:427–432
  43. Rice-Wray E, Aranda-Rossell A, Maqueo M, Goldzieher JW. Comparison of the long-term endometrial effects of synthetic progestins used in fertility control. Am J Obstet Gynecol. 1963;87:429–433
  44. Axelrod L, Goldzieher JW. Enzymic inadequacies of human polycystic ovaries. Arch Biochem Biophys. 1961;95:547–548
  45. Goldzieher JW, Young RL. Selected aspects of polycystic ovarian disease. Endocrinol Metab Clin North Am. 1992;21:141–171
  46. Goldzieher JW. Menopause — a deficiency disease. In:  Rock JR,  Faro S,  Gant NF,  Horowitz IR,  Murphy AA editor. Advances in Obstet Gynecol. St. Louis: Mosby; 1994;p. 159–178
  47. Goldzieher JW. Menopause: a major challenge for endocrinologists. Endocr Pract. 1996;2:339–341
  48. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;284:691–692
  49. Goldzieher JW. Media scan. Hormone replacement therapy and breast cancer risk. (Commentary) Contracept Rep. 2000;11:12–14
  50. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  51. Goodman N, Goldzieher JW, Ayala C. Critique of the report from the Writing Group of the WHI. Menopausal Med. 2003;10:1–4
  52. Clark JH. A critique of Women's Health Initiative studies (2002–2006). Nucl Recept Signal. 2006;4:e023
  53. McDonough PG. The randomized world is not without its imperfections: reflections on the Women's Health Initiative study. Fertil Steril. 2002;78:951–956
  54. Goldzieher JW. Heroic years. Letter to the editor. Fertil Steril. 2003;79:1258
  55. McDonough PG. Commentary. Fertil Steril. 2003;79:1258–1259

PII: S0010-7824(10)00098-3

doi: 10.1016/j.contraception.2010.03.008

Contraception
Volume 82, Issue 2 , Pages 119-124 , August 2010

Article Tools